User Posts: admin3
0
UK cancer patients deserve the best outcomes that science can offer
0

The future of cancer treatment has never been more exciting.  A third of new medicines being developed are cancer treatments, and a significant number ...

0
Phase 2 Trial Evaluates Annamycin Plus Ara-C In AML
0

The evaluation of Annamycin in combination with Ara-C (cytarabine) has launched in a new Phase 1B/2 trial, called MB-106, for patients with acute myeloid ...

0
Onvansertib May Elicit Responses in Pancreatic Cancer, Lung Cancer Subsets
0

Patients with metastatic pancreatic ductal adenocarcinoma responded to treatment with onvansertib in combination with standard of care, as demonstrated in ...

0
The Good Fight
0

I’ve never had a reason to examine mortality, not mine or others, it was just there. Our parents have long since passed, grieving surfaced briefly, however, ...

0
FDA Grants Fast Track Designation for New Breast Cancer Treatment
0

The U.S. Food and Drug Administration (FDA) has released a new fast track designation for IDE161, an inhibitor of poly (ADP-ribose) glycohydrolase (PARG) to ...

0
NALIRIFOX Regimen ‘New Possible Standard of Care’ for Some With Pancreatic Cancer
0

Patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with the NALIRIFOX regimen of Onivyde (irinotecan liposome injection) plus ...

0
Scars Fade, But Memories Don’t
0

Sometimes, I forget I had cancer. That seems a strange thing to say, but it’s true. It’s been almost 10 years since I was diagnosed with breast cancer. It ...

0
New T-Cell Therapy Shows Improved Response in Resistant Multiple Myeloma
0

Patients with relapsed/refractory multiple myeloma benefited from treatment with MCARH109, a CAR-T cell therapy targeting the “enigmatic” GPRC5D antigen ...

0
Oral Microbiome Connected With Mouth Sore Severity In Patients With Head and Neck Cancer
0

Among patients with squamous cell head and neck carcinoma, oral microbiome is associated with severity of oral mucositis (OM), an after-effect of ...

0
Tecvayli for MM Presents Similar Efficacy and Safety as Another Trial
0

Treatment with Tecvayli (teclistamab-cqyv) for real-world patients with relapsed/refractory multiple myeloma demonstrated similar efficacy results and a ...

User Deals: admin3
Browsing All Comments By: admin3
CML Alliance
Logo
Enable registration in settings - general
Compare items
  • Total (0)
Compare
0
Shopping cart